Home » Topics » HIV/AIDS, BioWorld Science

HIV/AIDS, BioWorld Science
RSS

GSK-744 LAP proves effective in monkeys with SHIV infection

March 7, 2013

Scientists at Bristol-Myers Squibb prepare novel agents for HIV infection

March 7, 2013

Health Canada declines to approve Theratechnologies' NDS for Egrifta

March 5, 2013

Biosantech initiates phase I/II trial of synthetic AIDS vaccine Tat Oyi

March 5, 2013

ViiV Healthcare grants voluntary license to increase access to HIV medicine for children

March 1, 2013

FDA grants priority review to dolutegravir NDA

Feb. 18, 2013

Tricyclic pim kinase inhibitors reported by the Spanish CNIO

Feb. 4, 2013

FAK inhibitors described at Merck & Co.

Feb. 4, 2013

New anti-properdin antibodies developed at the University of Pennsylvania

Feb. 1, 2013

Shionogi & Co. presents novel agents for HIV

Jan. 30, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...